BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 34057449)

  • 1. Growth, Purification, and Titration of Oncolytic Herpes Simplex Virus.
    Nguyen HM; Sah N; Humphrey MRM; Rabkin SD; Saha D
    J Vis Exp; 2021 May; (171):. PubMed ID: 34057449
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In Situ Cancer Vaccination and Immunovirotherapy Using Oncolytic HSV.
    Jahan N; Ghouse SM; Martuza RL; Rabkin SD
    Viruses; 2021 Aug; 13(9):. PubMed ID: 34578321
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Restriction of Replication of Oncolytic Herpes Simplex Virus with a Deletion of γ34.5 in Glioblastoma Stem-Like Cells.
    Peters C; Paget M; Tshilenge KT; Saha D; Antoszczyk S; Baars A; Frost T; Martuza RL; Wakimoto H; Rabkin SD
    J Virol; 2018 Aug; 92(15):. PubMed ID: 29793956
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Construction of Oncolytic Herpes Simplex Virus with Therapeutic Genes of Interest.
    Kahramanian A; Kuroda T; Wakimoto H
    Methods Mol Biol; 2019; 1937():177-188. PubMed ID: 30706396
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhancing Therapeutic Efficacy of Oncolytic Herpes Simplex Virus with MEK Inhibitor Trametinib in Some BRAF or KRAS-Mutated Colorectal or Lung Carcinoma Models.
    Zhou X; Zhao J; Zhang JV; Wu Y; Wang L; Chen X; Ji D; Zhou GG
    Viruses; 2021 Sep; 13(9):. PubMed ID: 34578339
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human Monocytes Are Suitable Carriers for the Delivery of Oncolytic Herpes Simplex Virus Type 1 In Vitro and in a Chicken Embryo Chorioallantoic Membrane Model of Cancer.
    Reale A; Krutzke L; Cadamuro M; Vitiello A; von Einem J; Kochanek S; Palù G; Parolin C; Calistri A
    Int J Mol Sci; 2023 May; 24(11):. PubMed ID: 37298206
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Replication and Spread of Oncolytic Herpes Simplex Virus in Solid Tumors.
    Hong B; Sahu U; Mullarkey MP; Kaur B
    Viruses; 2022 Jan; 14(1):. PubMed ID: 35062322
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oncolytic herpes simplex virus and immunotherapy.
    Ma W; He H; Wang H
    BMC Immunol; 2018 Dec; 19(1):40. PubMed ID: 30563466
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination of vinblastine and oncolytic herpes simplex virus vector expressing IL-12 therapy increases antitumor and antiangiogenic effects in prostate cancer models.
    Passer BJ; Cheema T; Wu S; Wu CL; Rabkin SD; Martuza RL
    Cancer Gene Ther; 2013 Jan; 20(1):17-24. PubMed ID: 23138870
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oncolytic Virus Encoding a Master Pro-Inflammatory Cytokine Interleukin 12 in Cancer Immunotherapy.
    Nguyen HM; Guz-Montgomery K; Saha D
    Cells; 2020 Feb; 9(2):. PubMed ID: 32050597
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Current State of Oncolytic Herpes Simplex Virus for Glioblastoma Treatment.
    Nguyen HM; Saha D
    Oncolytic Virother; 2021; 10():1-27. PubMed ID: 33659221
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systemic delivery of glycosylated-PEG-masked oncolytic virus enhances targeting of antitumor immuno-virotherapy and modulates T and NK cell infiltration.
    Liang Y; Wang B; Chen Q; Fu X; Jiang C; Lin Z; Zhuang Q; Zeng Y; Liu X; Zhang D
    Theranostics; 2023; 13(15):5452-5468. PubMed ID: 37908722
    [No Abstract]   [Full Text] [Related]  

  • 13. Oncolytic Herpes Simplex Virus-Based Therapies for Cancer.
    Aldrak N; Alsaab S; Algethami A; Bhere D; Wakimoto H; Shah K; Alomary MN; Zaidan N
    Cells; 2021 Jun; 10(6):. PubMed ID: 34207386
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development, optimization, and scale-up of suspension Vero cell culture process for high titer production of oncolytic herpes simplex virus-1.
    Shen CF; Burney E; Gilbert R; Elahi SM; Parato K; Loignon M
    Biotechnol J; 2024 Jan; 19(1):e2300244. PubMed ID: 37767876
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Eliciting an immune-mediated antitumor response through oncolytic herpes simplex virus-based shared antigen expression in tumors resistant to viroimmunotherapy.
    Ghonime MG; Saini U; Kelly MC; Roth JC; Wang PY; Chen CY; Miller K; Hernandez-Aguirre I; Kim Y; Mo X; Stanek JR; Cripe T; Mardis E; Cassady KA
    J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34599026
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination Therapy Using Ruxolitinib and Oncolytic HSV Renders Resistant MPNSTs Susceptible to Virotherapy.
    Ghonime MG; Cassady KA
    Cancer Immunol Res; 2018 Dec; 6(12):1499-1510. PubMed ID: 30352799
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oncolytic herpes simplex virus therapy for malignant glioma: current approaches to successful clinical application.
    Hua L; Wakimoto H
    Expert Opin Biol Ther; 2019 Aug; 19(8):845-854. PubMed ID: 31046478
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytokine-armed oncolytic herpes simplex viruses: a game-changer in cancer immunotherapy?
    Wang H; Borlongan M; Kaufman HL; Le U; Nauwynck HJ; Rabkin SD; Saha D
    J Immunother Cancer; 2024 May; 12(5):. PubMed ID: 38821716
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Herpes Simplex Virus Oncolytic Immunovirotherapy: The Blossoming Branch of Multimodal Therapy.
    Menotti L; Avitabile E
    Int J Mol Sci; 2020 Nov; 21(21):. PubMed ID: 33167582
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oncolytic herpes simplex viruses for the treatment of glioma and targeting glioblastoma stem-like cells.
    Kardani K; Sanchez Gil J; Rabkin SD
    Front Cell Infect Microbiol; 2023; 13():1206111. PubMed ID: 37325516
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.